Viracta Therapeutics, Inc.: share-based compensation expense

What this measure means

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Exact concept: us-gaap:ShareBasedCompensation. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2009-01-01 to 2023-12-31. The SEC response was captured on 2026-09-21.

This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.

Selected filing history

Related financial histories

• Viracta Therapeutics, Inc.: total assets
• Viracta Therapeutics, Inc.: total liabilities
• Viracta Therapeutics, Inc.: stockholders equity
• Viracta Therapeutics, Inc.: cash and cash equivalents
• Viracta Therapeutics, Inc.: net income or loss
• Viracta Therapeutics, Inc.: operating cash flow
• Viracta Therapeutics, Inc.: capital expenditure payments
• Viracta Therapeutics, Inc.: revenue
• Viracta Therapeutics, Inc.: contract revenue excluding tax
• Viracta Therapeutics, Inc.: financing cash flow
• Viracta Therapeutics, Inc.: investing cash flow
• Viracta Therapeutics, Inc.: retained earnings or deficit
• Viracta Therapeutics, Inc.: basic weighted-average shares
• Viracta Therapeutics, Inc.: diluted weighted-average shares
• Viracta Therapeutics, Inc.: basic earnings per share
• Viracta Therapeutics, Inc.: diluted earnings per share
• Viracta Therapeutics, Inc.: net property, plant and equipment
• Viracta Therapeutics, Inc.: operating income or loss
• Viracta Therapeutics, Inc.: current assets
• Viracta Therapeutics, Inc.: interest expense
• Viracta Therapeutics, Inc.: current liabilities
• Viracta Therapeutics, Inc.: current accounts payable
• Viracta Therapeutics, Inc.: operating expenses
• Viracta Therapeutics, Inc.: research and development expense
• Viracta Therapeutics, Inc.: common shares outstanding
• Viracta Therapeutics, Inc.: cash including restricted cash
• Viracta Therapeutics, Inc.: additional paid-in capital
• Viracta Therapeutics, Inc.: accumulated other comprehensive income or loss
• Viracta Therapeutics, Inc.: operating lease right-of-use asset
• Viracta Therapeutics, Inc.: operating lease liability
• Viracta Therapeutics, Inc.: other noncurrent assets
• Viracta Therapeutics, Inc.: other noncurrent liabilities
• Viracta Therapeutics, Inc.: accrued current liabilities
• Viracta Therapeutics, Inc.: prepaid expenses and other current assets
• Viracta Therapeutics, Inc.: pre-tax income or loss from continuing operations
• Viracta Therapeutics, Inc.: profit or loss including noncontrolling interests
• Viracta Therapeutics, Inc.: comprehensive income or loss
• Viracta Therapeutics, Inc.: net income available to common stockholders
• Viracta Therapeutics, Inc.: general and administrative expense
• Viracta Therapeutics, Inc.: depreciation, depletion and amortization
• Viracta Therapeutics, Inc.: other nonoperating income or expense
• Viracta Therapeutics, Inc.: interest paid, net
• Viracta Therapeutics, Inc.: proceeds from issuing common stock
• Viracta Therapeutics, Inc.: operating lease payments
• Viracta Therapeutics, Inc.: change in accounts payable

Inspect the source

Entity

Viracta Therapeutics, Inc. / CIK 0001061027

Captured

2026-09-21T17:17:49.171Z

SEC response SHA-256

46e1f007a1af4059ddd3a1b769d50f0b0415de87e9fba66a6561be1394613e67

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001061027.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))